ASCO 2013: Highlights in Chronic Myelogenous Leukemia

You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.

Release Date: June 19, 2013
Expiration Date: June 19, 2014

Expected time to complete this activity as designed: 60 minutes
There are no fees for participating in or receiving credit for this online activity.

Program Overview

In this educational activity, clinical experts discuss key findings relative to new and emerging treatments for chronic myelogenous leukemia (CML) from the 2013 ASCO meeting. Each module will focus on the latest data, on what the data means in the clinical setting, and how clinicians may effectively incorporate this information to improve patient care, and ultimately, patient outcomes.

Target Audience

This activity is designed for community oncologists, associated multidisciplinary clinical specialists, pharmacists, and nurses, who have an interest in enhancing their clinical skills in patients with CML.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Discuss treatment strategies based on recent clinical data
  • Describe advances in therapeutic approach in best practice and the integration of patient-centered care


Recently Approved Drugs for CML, Their Safety and Efficacy Data, and How They Are Currently Approved to Be Used Within the Treatment Continuum − Jorge Eduardo Cortes, MD

Nilotinib versus Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase – Stuart L. Goldberg, MD

Economic Benefits of Adequate Molecular Monitoring in Patients with CML − Stuart L. Goldberg, MD

Overcoming Resistance in Chronic Myelogenous Leukemia – Michael J. Mauro, MD

Instructions for Participation and Credit

This activity is eligible for credit through June 19, 2014. After this date, this activity will expire and no further credit will be awarded.

  1. Read the target audience, learning objectives, and faculty disclosures.
  2. You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
  3. Complete the educational content as designed.
  4. Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
  5. Complete the activity evaluation survey to provide feedback and information useful for future programming.
  6. Certificates may be printed immediately after successfully completing the post-test and activity evaluation.

Faculty Biographies

Jorge Eduardo Cortes, MD
Professor of Medicine and Deputy Chair
Chief of the CML Section
Department of Leukemia
The University of Texas, MD Anderson Cancer Center
Houston, Texas

Dr. Jorge Cortes received his medical degree from Faculty of Medicine of the National Autonomous University of Mexico along with postgraduate training at The National Institute of Medical Sciences and Nutrition Salvador Zubirán. He also completed a hematology fellowship at The University of Texas Health Science Center at Houston, and a hematology/oncology fellowship at The University of Texas MD Anderson Cancer Center. Dr. Cortes is professor of medicine and deputy chair, and is also the chief of the CML Section in the Department of Leukemia at The University of Texas, MD Anderson Cancer Center.

Dr. Cortes has authored hundreds of peer-reviewed articles, abstracts, book chapters, and medical publications. He is editor-in-chief of Clinical Leukemia, and Current Malignant Hematology Reports, and is on the editorial board of Clinical Cancer Research, Leukemia, and Journal of Clinical Oncology. In addition, Dr. Cortes serves on the Board of Directors for The Leukemia & Lymphoma Society. His clinical interests focus on new drug development and the management of patients with acute and chronic leukemia.

Stuart L. Goldberg, MD
Chief, Division of Leukemia
John Theurer Cancer Center
Hackensack, New Jersey

Dr. Stuart Goldberg received his medical degree from Pennsylvania State University, Milton S. Hershey Medical Center. He completed his internal medicine residency and his hematology-oncology fellowship at George Washington University Medical Center. He also completed a bone marrow transplantation fellowship at Fred Hutchinson Cancer Research Center. Dr. Goldberg is chief, Division of Leukemia, John Theurer Cancer Center in Hackensack, New Jersey.

Dr. Goldberg specializes in medical oncology and leukemia, and is board certified in medical oncology, hematology and internal medicine. He is a member of the American College of Physicians, American Society of Blood and Marrow Transplantation, American Society of Hematology, American Society of Clinical Oncology, Eastern Cooperative Oncology Group, Southwest Oncology Group, and the Myelodysplastic Foundation, among others. Dr. Goldberg specializes in treating all types of leukemia and myelodysplastic syndromes with a variety of treatment modalities, including chemotherapy and stem cell transplantation.

Michael J. Mauro, MD
Associate Professor
Oregon Health & Science University
Portland, Oregon

Dr. Michael Mauro received his medical degree from Dartmouth Medical School. He completed his residency at Cornell University Medical Center and his fellowship in hematology-oncology at Weill Medical College of Cornell University - New York Presbyterian Hospital. Dr. Mauro is currently an associate professor at the Oregon Health & Science University (OHSU) in Portland.

Dr. Mauro has American Board of Internal Medicine certification in both medicine and hematology. He has done extensive research at OHSU over the last decade into chronic myelogenous leukemia (CML), myeloproliferative diseases, and how to treat them. His passion is working with patients in difficult situations, including side effects from treatment or disease that is not responding well to treatment. He helps patients make crucial decisions about changes in treatment or alternative options such as stem cell transplants. Dr. Mauro has a passion for bringing new treatments to patients through clinical trials. He prides himself on carefully explaining blood diseases, empowering patients to participate in decision-making, and monitoring their progress. He makes sure patients understand every option available in their situation, and which might work best for their disease, depending on results and progress and the most current treatment options to those living with CML and related conditions.


Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 1.0 contact hour of Continuing Education Credit. Universal Activity Number: 827-0000-13-356-H01-P. Knowledge-based CPE activity.

In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when registering for a CPE program. Please make sure to provide this information in your Member Profile accessed through the Member Center on the home page of this site.

Accreditation Statement: MediCom Worldwide, Inc., 101 Washington Street, Morrisville, PA 19067 is approved by the California Board of Registered Nursing, Provider Number CEP11380. MediCom designates this CNE activity for 1.0 contact hour. Program Number: 13-356-320


As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.

Faculty Disclosures

Dr. Jorge Cortes has received honoraria as a consultant from ARIAD Pharmaceuticals, Pfizer Inc., Inc., and Teva Pharmaceuticals, as well as grant support related to research activities from ARIAD, Bristol-Myers Squibb, ChemGenex Pharmaceuticals Ltd, Novartis AG, and Pfizer.

Dr. Stuart Goldberg has received honoraria related to formal advisory activities and speakers’ bureau activities from ARIAD Pharmaceuticals, Inc., Bristol-Myers Squibb, and Novartis AG.

Planning Committee Disclosures

The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Joan Meyer, RN, MHA, executive director, and Jan Markind, PharmD, CMPP, director, scientific affairs, have no relevant financial relationships.

Peer Reviewer Disclosure

In accordance with MediCom Worldwide, Inc. policy, all content is independently peer reviewed for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.

Off-Label Disclosures/Investigational Disclosures

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, attendees/participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program.

Dr. Cortes has indicated that he does not intend to discuss off-label uses of drugs, mechanical devices, biologics or diagnostics approved by the US Food and Drug Administration (FDA) for use in the US.

Dr. Cortes has indicated that he does not intend to discuss investigational drugs, mechanical devices, biologics or diagnostics not approved by the FDA for use in the US.

Dr. Goldberg has indicated that he does intend to discuss off-label uses of drugs, mechanical devices, biologics or diagnostics approved by the US Food and Drug Administration (FDA) for use in the US.

Dr. Goldberg has indicated that he does intend to discuss investigational drugs, mechanical devices, biologics or diagnostics not approved by the FDA for use in the US.

Hardware/Software/Internet Requirements

MediCom Worldwide, Inc. requires Internet Explorer® version 9.0 or higher, the latest version of Google Chrome, or the latest version of Safari, a computer running Windows® Vista, Windows® 7, or Mac OS X, 512MB of RAM or greater, 1.5 GHZ or faster processor, and a screen resolution of 1024x768 or higher. Certain educational activities may require additional software to view. These activities will be marked with the information and/or links to the required software. That software may include Adobe® Flash® Player, Adobe® Acrobat®, Windows Media® Player, and/or Microsoft® Silverlight™.

If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Teva Pharmaceuticals and Novartis.

©2013 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.

You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.